A. Bulgaru

Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineeredTM monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors (2007)

Goel, S., Bauer, R. J., Desai, K., Bulgaru, A., Iqbal, T., ...

Background: ING-1 is a high-affinity, human engineered™ monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels...

Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors (2003)

Goel, S., Bulgaru, A., Hochster, H., Wadler, S., Zamboni, W., Egorin, M., ...

Background: The aim of this study was to determine the maximum tolerated dose, recommended phase II dose (RPTD) and toxicities of the FOG regimen (infusional 5-fluorouracil, oxaliplatin,...